Skip to content
Earendil
-
Genentech signs US$1.5B Earendil deal to develop AI-designed bispecific antibodies
Earendil, a biotechnology company operating in the US and China, will identify and develop bispecific antibody programmes based on target combinations agreed with Genentech.